A B S T R A C T We have studied the in vitro effects of dexamethasone on isolated rat adipocytes at concentrations of dexamethasone therapeutically achieved in man. Glucose oxidation, glucose transport, and insulin binding were assessed. In dexamethasone-treated cells, glucose oxidation was decreased by 30-40% both in the absence of insulin (basal state) and at low insulin levels (less than 25 AsU/ml). At maximally effective insulin levels (over 100 F'U/ml) no differences existed between control and treated cells. If glucose transport were the ratelimiting step for glucose oxidation in the basal state and at low (submaximal) insulin levels, but not at maximally effective insulin concentrations, then these data could be explained by postulating that dexamethasone has a direct affect on glucose transport and does not affect intracellular oxidative pathways. We tested this hypothesis by directly assessing glucose transport in dexamethasone-treated cells. Glucose transport was assessed by measuring the uptake of [14C]2-deoxy glucose. These studies demonstrated a 30-40% decrease in 2-deoxy glucose uptake by treated cells both in the basal state and at all insulin concentrations. Thus, a direct glucocorticoid effect on the glucose transport system seems to account for the decreased ability of dexamethasone-treated cells to oxidize glucose. Since dexamethasone treatment leads to decreased insulin binding to adipocytes in vivo, we examined the possibility that the in vitro decreases in insulin-mediated glucose transport could be due to decreased insulin receptors. Insulin binding to control and treated adipocytes was measured, and no differences were found. Therefore, in contrast to previously reported in vivo studies, adipocytes treated in vitro with Dr. Olefsky is a Restarch Associate with the Veterans Administration (MRIS #6488).
INTRODUCTION
Insulin resistance, as manifested by glucose intolerance in the face of hyperinsulinemia, is a known sequela of in vivo corticosteroid administration (1, 2) . It is well established in vitro that corticosteroids decrease the ability of isolated adipocytes (3) (4) (5) and muscle tissue (6) to oxidize glucose, and the potential relationship between these in vitro observations and in vivo insulin resistance is obvious. The initial studies of this in vitro effect of corticosteroids demonstrated that glucose oxidation could be inhibited in the absence of insulin (basal oxidation), but that this inhibition could be overcome by insulin (3) (4) (5) . This led to the hypothesis that there were two distinct glucose transport systems: a basal system and an insulin-sensitive system, and that only the basal glucose transport system was sensitive to glucocorticoid inhibition (3) (4) (5) . More recently, Czech and Fain (7) have reported that the inhibitory effects of dexamethasone on adipocyte glucose oxidation can only be observed where glucose transport is thought to be rate-limiting, and have therefore suggested that only one glucose transport system exists. To study this question, we have directly assessed glucose transport and oxidation in control and dexamethasone-treated cells.
We have previously demonstrated that in vivo administration of dexamethasone leads to a decrease in the number of insulin receptors on rat adipocytes and hepatocytes (8) , and Kahn et al. (9) have reported similar results using rat liver plasma membranes. This led us to speculate that the dexamethasone-induced decrease in
The Journal of Clinical Investigation Volume 56 December 1975'1499-1508 inistulin-mediated glucose metabolism (7, 10) miglht be (dtie to decreased niumiiber-s of inistulini receptor s. To test this hypothesis, wN-e studied the direct in -itro effects of dexamIIethasonle oIn instllii bindinig to isolated adipocytes in conjunction with the measuremlenits of glucose metabolism. Lastly, in these current studies, wve sought to gain iniformation about the initerrelationslhips betw-een insulin biniding to receptors alnd insuliln's celluilar actioin (glucose transport and oxidation) in the samiie cells.
METHODS
Materials. Porcinie ionocoml)onent inisuilini wXXas genierously supplied by Dr. Ronald Clhanice of the Eli Lilly and Company (Indianapolis, Ind.). Na Preparationt of isolatcd adipoctes. ' Male Sprague-Dawley rats were used for all experimeints. All studies wN-ere performed in the morning oIn animals that hadl free access to standard rat chow. Animals were stunned by a blow to the head and decapitated, and epididlyvlal fat pads w-ere removed. Isolated fat cells xere prepared by shaking at 37°C for 60 min in Krebs-Ringer bicarbonate buffer containiing collagenase (3 mg/ml) and albumin (40 mg/ml), according to the method of Rodbell (11) . Cells were then filtered tlhroughi 250-riml nyloni meslh, centrifuged at 400 rpm for 4 min, and waslhed three times in buffer (12) .
Iodiniationt of isulin1. "5I-insulin Was prepared at a sp act of 100-150 ,uCi/Ag according to Freychet and coworkers' modification (13) of the method of Hunter and Greenwood (14) , as previously described (15) . This preparationl has an average of 0.24.3 atoms of 125I/insulinl molecule. Freychet (13) and others (16, 17) have demonistratedl that wvith this degree of iodination, over 90% of the iodlinated species is monoiodinated insulin, whiclh retains full biological activity (13, 17) .
Biniding stuidics. Isolated fat cells were suspended in a buffer containing 35 miM Tris, 120 mnM NaCl, 1.2 mM MIgS04, 2.5 mM KCl, 10 mM glucose, 1 mIM EDTA, and 1% BSA (18) , pH 7.6, and incubated with 15I-insulin and unlabeled insulin in siliconized 10-mil Erlenmeyer flasks in a 24'C shaking water bath as previously described (8, 12, 19) . Methodologic studies (data nct showx-in) have indicated that optimal steady-state bindinlg conditions are achieved at 24°C after 45 min of incubation (12) . The incubations were terminated as described by Gammeltoft and Gliemann (20) (26) .
RESULTS
Glucose oxidation studies. The effects of dexamethasone on glucose oxidation can be seen in Fig. 1 . Basal glucose oxidation (in the absence of insulin) is decreased 30% in the dexamethasone-treated cells. In the presence of submaximal insulin concentrations, this decrease in '4CO2 production by dexamethasone-treated cells is still present, but at a maximally effective insulin concentration, no difference in glucose oxidation between control and dexamethasone-treated cells was observed. Increasing the dexamethasone concentration 10-fold did not change these results, indicating that the data represent the maximal dose effect of the corticosteroid. Since the glucose concentration used in these studies was relatively low (2 mM), glucose transport is probably the rate-limiting step in the absence of and at low levels of insulin. On the other hand, at the maximally effective insulin concentration, the amount of glucose transported into the cell could be great enough to saturate the oxidation pathways. Thus, if dexamethasone exerted its effects at the level of glucose transport, and did not affect the intracellular oxidative processes, one could see decreased glucose oxidation at basal conditions and at All P values were obtained-by use of the paired t test. Time (min) FIGURE 2 Time course of 2-deoxy-glucose uptake in the absence of (basal) and presence of insulin (5 ng/ml or 120 AU/ml). Incubations were carried out at 24°C in the presence of 0.28 mM 2-deoxy-glucose. Since 2-deoxy-glucose uptake is a linear function of cell concentration (not shown) up to at least 6 X 10' cells/ml (higher than used in any of the studies presented), all data are normalized to a cell concentration of 10' cell/ml.
submaximal insulin levels, with normal rates of glucose oxidation at maximal insulin concentrations.
2-Deoxy glucose uptake stuidies. To test this hypothesis, glucose transport was compared in control and dexamethasone-treated cells. Glucose transport was assessed by direct measurement of the rate of accumulation of the nonmetabolyzable sugar 2-deoxy-glucose, and to be confident that this approach allowed us to assess the glucose transport process, a number of initial studies were necessary.
Time-course experiments demonstrated that 2-deoxyglucose uptake was linear until at least 8 min (Fig. 2) at 24°C, both in the absence of insulin and at maximally effective insulin concentrations. These experiments were conducted at a 2-deoxy-glucose concentration of 0.28 mm, and comparable linearity of uptake (until 5 min) was seen at 20 mM (data not shown). Therefore, all subsequent experiments were terminated at 3 min of incubation. As with other hexose transport systems, initial uptake rates were temperature-dependent (26) (27) (28) , with 3-min 2-deoxy-glucose uptake being 50-70% greater at 37°C than at 240 (Table I ). The sterospecificity of the system is shown by measuring the effect of other sugars on 2-deoxy-glucose uptake. This was done by incubating cells and 2-deoxy-glucose (1 mM) with other sugars such as L-glucose, D-fructose, 3-0-methyl-glucose, and phlorizin at a concentration of 10 mM. Under these conditions, 2-deoxy-glucose uptake was not affected by D-fructose or L-glucose, but was 57% inhibited by 3-0-methylglucose, 70% inhibited by D-glucose, and 80% inhibited by phlorizin.
The effect of substrate concentration on the initial rate (27) (28) (29) 31) . Furthermore, when the data were corrected for the diffusion factor (26) (27) (28) (29) , and plotted on a Lineweaver-Burk graph (Fig. 3B) (Fig. 3) , 2-deoxy-glucose uptake in the presence of cytochalasin B is the same with or without insulin (Fig. 4A) . In contrast, when glucose oxidation is measured under similar conditions (Fig.  4B) , insulin exerts stimulatory effects even in the presence of cytochalasin B. In these experiments, high glucose concentrations were used, since at these concentrations appreciable amounts of sugar can diffuse into the cell (Fig. 3) . Consequently, even though insulin cannot increase glucose transport in the presence of cytochalasin B, enough glucose enters the cell by diffusion so that a stimulatory effect distal to transport that promotes oxidation can be measured. The data of Fig. 4 are consistent with such an effect.
Comparison of 2-deoxy: glucose uptake in control versus dexamethasone-treated cells. Uptake of 2-deoxyglucose is decreased in dexamethasone treated cells. These data are seen in Fig. 5 , and support the hypothesis that dexamethasone exerts its effects at the level of glucose transport. Sugar uptake is decreased in the dexamethasone-treated cells in the absence of insulin (basal transport) and at all levels of insulin stimulation. Thus, uptake is 30-40% less by treated cells under all conditions, and this decrease is quantitatively comparable to the decreases in glucose oxidation noted in Fig. 1 . However, if the data are expressed as the percent increase above the basal rate of uptake (Fig. 5B) andl presenice (0-0) of insulin (5 ng/ml or 120 /uU/mil).
The 3-0-methyl glucose concentration w-as 20 (28, 35, 38) . Fig. 7A shows the uptake of 3-0-methyl glucose as a function of time. Because 3-0-methyl glucose is not phosphorylated (and consequently trapped inside the cell), equilibrium is rapidly reached due to significant efflux of the sugar. (8) , it seemed possible to speculate that the decrease in insulin-mediated glucose oxidation and transport just described was due to a dexametlhasone-induced decrease in insulin binding. To study this possibility, insulin binding was determined with control and dexamethasone-treated cells, and the results of these studies are presented in Fig. 8 . As can be seen, the ability of both groups of cells to bind insulin is identical, indicating that under these experimental conditions dexamethasone does not affect insulin binding in vitro. The concentration of dexamethasone used in these experiments was 8 X 10' M, which should be fully effective. However, increasing the dexamethasone concentration 10-fold or prolonging the preincubation period with the glucocorticoid to 5 h did not change these results.
Since dexamethasone did not decrease insulin binding (Fig. 8) , but since dexamethasone did decrease glucose transport (Fig. 5A) , one can see that for any given amount of insulin bound per cell, the dexamethasonetreated adipocytes will transport less glucose. However, separate paired experiments and all data were corrected for nonspecific binding by subtracting the amount of radioactivity remaining bound at an insulin concentration of 200 ,ug/ml from the amount of radioactivity in the cell pellet at all other insulin concentrations (8, 12, 19) . In these studies insulin-mediated sugar uptake at the indicated insulin concentrations. Since Fig. 4B demonstrates that the percent increment above basal uptake is the same for control and dexamethasone-treated cells, this curve is also the same for both groups of cells. Closed circles represent the percent of maximal specific insulin binding for both groups of cells. For this analysis, maximal insulin binding is taken as the amount of insulin specifically bound at a total insulin concentration of 100 ng/ml (or 2,400 ,U/ml) (12) .
since the insulin-mediated increment in glucose transport above basal rates was the same in both groups of cells (Fig. 5B) , it is probable that the interaction between insulin-receptor complexes and the glucose transport system is unaffected by dexamethasone. In both groups of cells, however, it is clear that increases in insulin concentration lead to increases in the amount of insulin bound far above the insulin concentration that causes maximal glucose transport. The relationship between the dose-response curves for insulin binding and glucose transport is seen in Fig. 9 . These data show that maximal insulin-stimulated glucose transport occurs when only 15% of the available insulin receptors are occupied.
Mllechanismit of the dexamethasone effect. Glucocorticoids are known to initiate their effects by specifically binding to cytoplasmic receptors (40) . Consistent with this mechanism is the 1-2-h time lag before effects of dexamethasone on glucose metabolism can be observed (4, 5, and unpublished observations). Furthermore, we have found that 8 X 10' M progesterone did not inhibit glucose oxidation (Table III) , indicating that the observed effects of dexamethasone at this concentration were not due to nonspecific steroid-membrane interactions. Additionally, when adipocytes were exposed to dexamethasone (8 X 10' M) in the presence of excess amounts of progesterone (10' M), no effect of dexamethasone on glucose transport was observed (Table  III) The conclusions drawn from the studies of 2-deoxyglucose uptake are valid only insomuch as this measurement reflects glucose transport, and the validity of this concept has been recently reviewed (38) . For example, Renner et al. (27) have extensively studied the glucose transport system in rat hepatoma cells, and have concluded that "2-deoxy-glucose is the substrate of choice as a model for glucose transport" since it is phorphorylated by cells (but not further metabolized) and consequently is trapped inside the cell allowing for readily measurable periods of maximal uptake. That this is the case for adipocytes can be seen in the time-course data of Fig. 2 . However, since 2-deoxy-glucose is phosphorylated, it is conceivable that the hexokinase reaction is rate limiting. If so, then uptake would reflect phosphorylation more closely than transport, and the differences we have found between control and dexamethasone-treated cells may be due to differences in hexokinase activity rather than transport. We beliver this is highly unlikely for the following reasons: (a) the effects of dexamethasone on 3-0-methyl glucose uptake (which reflects only transport) are the same as its effects on 2-deoxy-glucose uptake. (b) The Km values we measured for glucose transport are comparable to those reported by other workers (26) (27) (28) 38) , and the effect of insulin to increase Vtnas without changing Km is the same as that found by Czech et al. (28) , who studied glucose transport in isolated brown fat cells with 3-0-methyl glucose. (c) Cytochalasin B, which inhibits facilitated hexose transport and does not affect the hexokinase reaction (26) (27) (28) (29) (30) , obliterated the saturable component of 2-deoxy-glucose uptake (Fig. 3) . (d) Since the 3-min uptake of 2-deoxyglucose determined in these studies is a measure of initial uptake rate, and since only a small fraction of the total sugar taken up at this time is in the form of free 2-deoxy-glucose (Table II) , it is very unlikely that the capacity of the hexokinase reaction is exceeded. (e) Bernstein and Kipnis (10) have shown that adipocyte hexokinase is normal in rat adipocytes 4 h after the in vivo administration of dexamethasone, and we have found no effect of the glucocorticoid on hexokinase activity after 3 h of in vitro incubation. (f) The data on glucose oxidation at maximal insulin levels ( Fig. 1 (Fig. 6) , dexamethasone-treated cells are capable of taking up much more 2-deoxy-glucose than during low sugar concentration (0.28 mM) and maximal insulin levels (5 ng/ml), as described in Fig. 5 .
Since adipocytes isolated from dexamethasone-treated rats have a decreased ability to bind insulin (8) , it seemed reasonable to believe that the dexamethasoneinduced decrease in insulin-mediated glucose oxidation and transport was related to a similar dexamethasoneinduced decrease in insulin binding. However, the data in Fig. 8 demonstrate that dexamethasone does not decrease insulin binding to adipocytes in vitro. These findings are in apparent contrast to the in vivo observations that isolated adipocytes and hepatocytes obtained from rats treated with dexamethasone have decreased insulin receptors (8) . The explanation for this difference between the in vitro and in vivo effects of dexamethasone on insulin binding is not clear. Gavin et al. (42) have demonstrated in vitro that sustained high concentrations of insulin can lead to decreased numbers of insulin receptors on cultured lymphocytes and have suggested that this same phenomenon might operate in vivo. Consequently, one possibility is that in vivo dexamethasone induces increased plasma insulin levels, which lead to a decrease in insulin receptors on cells. Another possibility is that more time is needed for the effects of dexamethasone on insulin binding to develop than can be achieved in these in vitro studies. Obviously, other potential explanations exist.
The data clearly show that for any given amount of insulin bound, dexamethasone: treated adipocytes take up less 2-deoxy-glucose than untreated cells. However, since basal uptake rates are decreased to the same extent as are the insulin-mediated uptake rates (i.e., insulinmediated increments in glucose transport are the same in both groups of cells) it is likely that the coupling between occupied insulin receptors and the glucose transport system is not affected by dexamethasone. However, the overall relationship between the amount of insulin bound and insulin action in both groups of cells is less clear. As seen in Fig. 9 , maximal glucose transport occurs at an insulin concentration at which only 15% of the available receptors are occupied. This relationship between binding and function has been observed for other systems (43) and for other hormones (44, 45) . Possible interpretations of this observation of apparent "spare" receptors have been recently reviewed (44, 45) .
An additional interesting aspect of these studies was the observation that insulin had greater stimulatory effects on glucose oxidation than on transport. This suggested that insulin can promote oxidation by stimulating an intracellular step in the oxidative process as well as by increasing glucose transport. This idea was confirmed by finding that insulin could still promote glucose oxidation in the presence of cytochalasin B (which inhibits insulin's effects on transport). This posttransport effect adds a new dimension to the currently held concept that insulin promotes glucose oxidation by increasing transport (36, 37) . Clearly, further studies will be necessary to delineate the locus and quantitative importance of this effect in terms of overall glucose metabolism.
In summary, these studies have demonstrated that dexamethasone in vitro inhibits glucose transport in both the basal and insulin-stimulated state, and appears not to affect primarily the intracellular enzymes responsible for glucose oxidation. Furthermore, in vitro, dexamethasone does not decrease insulin binding to adipocytes, in contrast to its in vivo effects. Thus, at least two mechanisms can be suggested to explain the insulin-resistant state associated with in vivo corticosteroid administration: (a) a decrease in insulin binding to cells, and (b) direct inhibition of the glucose transport system.
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